Inhibition of human monoamine oxidase A and B by 5-phenoxy 8-aminoquinoline analogs
摘要:
8-Aminoquinolines (8-AQs) are important class of anti-infective therapeutics. 5-Phenoxy 8-aminoquinoline analogs have shown improved metabolic stability compared to primaquine. In view or predictive role of monoamine oxidases (MAO) in metabolism of 8-aminoquinolines the 5-phenoxy analogs were evaluated in vitro for the inhibition of recombinant human MAO-A and MAO-B. The analogs were several folds more potent inhibitors of MAO-A and MAO-B compared to primaquine, the parent drug, with selectivity for MAO-B. 5-(4-Trifluoromethylphenoxy)-4-methylprimaquine (6) Inhibited MAO-B with IC50 value of 150 nM (626-fold more potent than primaquine). These results will have important implications in optimizing metabolic stability of 8-AQs to improve therapeutic value and also indicate scope for development of 8-AQs as selective MAO inhibitors. (C) 2012 Elsevier Ltd. All rights reserved.
It has been found that one of the enantiomers of 8-aminoquinoline antiparasitic compounds is surprisingly more active than the other enantiomer against parasitic infections including opportunistic parasitic infections. These enantiomers as well as pharmaceutical compositions containing pure enantiomers are disclosed. Also disclosed is a novel class of 8-aminoquinolines which contain a tri-substituted phenoxy substitution.
(EN) It has been found that one of the enantiomers of 8-aminoquinoline antiparasitic compounds is surprisingly more active than the other enantiomer against parasitic infections including opportunistic parasitic infections. These enantiomers as well as pharmaceutical compositions containing pure enantiomers are disclosed. Also disclosed is a novel class of 8-aminoquinolines which contain a tri-substituted phenoxy substitution.(FR) On a découvert que l'un des énantiomères des composés antiparasitaires à base de 8-aminoquinolines est considérablement plus actif que les autres de ces énantiomères contre les infections parasitaires, y compris les infections parasitaires opportunistes. La présente invention concerne donc de tels énantiomères ainsi que des compositions pharmaceutiques contenant des énantiomères purs. L'invention concerne également une nouvelle classe de 8-aminoquinolines à substitution phénoxy trisubstitué.
Medicament comprising (-)-8-[(4-amino-1-méthylbutyl)amino]-5-(3,4-dichlorophénoxy)-6-méthoxy-4-méthylquinoline for the treatment of parasitic and opportunistic infections